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180 revealed no differences except a signiﬁcantly greater risk of
viral infections in TCD recipients from day 0-42 (TCD vs BM RR
3.5, p  0.02). After day 180, TCD recipients had the greatest
infection risk, whereas UCB recipients had the lowest risk TCD vs
BM RR 3.1, p 0.03; UCB vs BM RR 0.5, p 0.23). Multivariate
Cox regression analysis revealed that age 8 years, TCD, and
severe acute GVHD were each associated with increased infection
risk. These data suggest that the immune reconstitution after UCB
transplantation is superior to that seen with TCD, and is as good
as with unmanipulated BM.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Shpall, E.J.1, McNiece, I.K.2, de Lima, M.1, McMannis, J.D.1, Robin-
son, S.1, Peled, T.3, Champlin, R.E.1, 1. The M.D. Anderson Bone
Marrow Transplant Department, Houston, TX; 2. Johns Hopkins On-
cology Center, Baltimore, MD; Gamida Cell Ltd.
Umbilical cord blood (CB) from unrelated donors is increasingly
used to restore hematopoiesis after myeloablative or more recently,
nonmyeloablative therapy. CB transplants are associated with
higher rates of delayed and failed engraftment than are bone
marrow transplants, particularly for adult patients. At the Univer-
sity of Colorado, we studied the ex vivo expansion of CB in an
attempt to improve time to engraftment and reduce the graft
failure rate in the recipients. In the study, 43 patients with hema-
tologic malignancies (n  40) or breast cancer (n  3) received
high-dose therapy followed by unrelated allogeneic CB transplan-
tation [1]. A fraction of each patient’s CB allograft was CD34-
selected and cultured ex vivo for 10 or 14 days prior to transplan-
tation in deﬁned media with stem cell factor (SCF), granulocyte
colony-stimulating factor (G-CSF), and megakaryocyte growth
and differentiation factor (MGDF). The remainder of the CB graft
was infused without further manipulation. Two sequential cohorts
of patients were accrued to the study. The ﬁrst cohort had 40% and
the second cohort had 60% of their CB graft expanded. This study
demonstrated that the CD34 selection and ex vivo expansion of CB
prior to transplantation is feasible. The engraftment failure rate
was relatively low, and the time to neutrophil in large adults was in
the range reported for pediatric recipients of much larger CB cell
doses.
In the successor cord expansion trial being conducted at the
M.D. Anderson Cancer Center, several changes in the approach
have been made. Patients with hematologic malignancies are now
being randomized to receive either two unmanipulated CB units or
one unmanipulated unit and one unit from which all the cells are
expanded ex vivo. For the patients randomized to expansion, on
day 14 one of their cord units is AC133-selected using the
CliniMACS device. The AC133-negative fraction containing the
T cells is frozen and the AC133 fraction is cultured ex vivo for 14
days in media containing SCF, G-CSF and thrombopoietin
(TPO). Following administration of the preparative regimen, on
Day 0, the second unmanipulated CB unit is infused, followed by
the thawed AC133-negative fraction and ﬁnally, the fraction which
has been in culture for two weeks. This trial was recently initiated
and accrual is in progress.
Another expansion trial technology involves the use of a copper
chelating agent, which has been shown by Peled et al to enhance
the expansion of a more primitive CD34 CB population when
combined with early acting growth factors. A clinical trial employ-
ing this technology is in progress at M.D. Anderson. Patients with
hematologic malignancies undergoing CB transplantation, with a
unit that is cryopreserved in two fractions are eligible for the study.
Twenty one days prior to infusion, the AC133 cells are isolated
from the smaller cord fraction using the CliniMACS device and
cultured for three weeks in media containing interleukin-6 TPO,
FLT-3, SCF, and the copper chelator tetraethylenepentamine
(TEPA). The patients then receive high-dose therapy with the
infusion of the larger, unmanipulated CB fraction on day 0, and
infusion of the smaller expanded fraction of day1. Thus far eight
patients have been enrolled on the study and the results will be
forthcoming.
Future directions include the use of mesenchymal stem cells as a
supportive stroma for the expansion of CB mononuclear cell pro-
genitors, developed by McNiece et al. This approach would obvi-
ate the need for CD34 or AC133-selection, as those procedures are
associated with substantial losses of CD34 CB cells
1. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex
vivo expanded cord blood. Biol Blood Marrow Transplant.
2002;8:368-376.
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CGMP MANUFACTURE OF THE MULTIPOTENT ADULT PROGENITOR
CELL (MAPC) AND STRATEGY FOR CLINICAL TESTING
Wagner, J.E., Verfaillie, C.M. Blood and Marrow Transplant Program
and Stem Cell Institute, University of Minnesota, Minneapolis, MN.
MAPC are a rare cell population found in adult bone marrow
(BM) that proliferate for extended periods without obvious senes-
cence. MAPC differentiate into mesodermal, neuroectodermal and
endodermal tissues. Further, MAPC contribute to most somatic
tissues when injected into an early blastocyst, and can engraft in
post-natal animals where they can differentiate into tissue-speciﬁc
cell types. Therefore, we hypothesize that MAPC may be useful in
the treatment of a variety of degenerative and inherited diseases
and traumatic injury. Prior to clinical testing, however, MAPC
must be produced in accordance with cGMP. This will require: 1)
production of clinical grade reagents (i.e., sterile, endotoxin and
mycoplasma free), 2) optimization of process components to min-
imize surface areas required for cell expansion, 3) deﬁnition of a
closed cell expansion system integrated with blood cell processing
procedures and equipment, 4) process validation and establishment
of quality assurance documentation, and validation of the assays
themselves used for quality control (QC) and product release.
After clinical manufacture, MAPC lot release criteria will include
a demonstration of: 1) purity as measured by cell surface antigen
expression (MAPC are CD45neg, MHCneg, CD13) and quan-
titative RT-PCR for the transcription factor oct4; 2) proliferative
capacity as measured ability to be promulgated in culture for 70
doublings without telomere shortening and without cytogenetic
abnormalities, and 3) pluripotency, as demonstrated by ability to
differentiate into tissue-speciﬁc cells of each lineage. In parallel to
efforts to develop a large scale clinical manufacture procedure,
there has been considerable effort to the selection of a clinical
model for the testing of MAPC. As it is hypothesized that MAPC
will distribute and proliferate in tissues of various organs, partic-
ularly in response to tissue injury, the ﬁrst clinical trial will be in
recipients of high dose chemoradiotherapy in whom high regimen
related toxicity (i.e., as evidenced by injury to the gastrointestinal
tract, liver and lung) severely limits survival.
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ISOLATION OF NON-HEMATOPOIETIC STEM CELLS FROM UMBILICAL
CORD BLOOD
Wernet, P., Fischer, J., Caplan, A., Zanjani, E., Müller, H.W., Knip-
per, A., Kögler, G.
An intrinsically pluripotent, CD45 negative population from
placental cord blood, termed unrestricted somatic stem cells
(USSC) as a rare population grows adherently and can be expanded
to large quantities of cells without losing pluripotency. Thus, in
vitro USSC homogeneous differentiation into osteoblasts, chon-
droblasts, adipocytes, hematopoietic and neural cells including
astrocytes and neurons expressing neuroﬁlament, sodium channel
protein and various neurotransmitter phenotypes are demon-
strated. Stereotactic implantation of USSC into intact adult rat
brain revealed that human Tau-positive cells persisted for several
months, showing migratory activity and a typical neuron-like mor-
phology. In vivo differentiation of USSC along mesodermal and
endodermal pathways was demonstrated in animal models. Bony
reconstitution was observed after transplantation of USSC-loaded
calcium phosphate cylinders in nude rat femurs. Chondrogenesis
occurred after transplanting cell-loaded Gelfoam sponges into
nude mice. Transplantation of USSC in a non-injury model, the
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